AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions, and listings, of claims in this application.

Listing of Claims

1. (currently amended) The composition according to claim 16, comprising a protein in crystalline form wherein the protein crystal has a crystal lattice in a $P4_122$ space group and ~~having~~ unit cell dimensions, +/- 5%, of a=88.80Å b=88.80Å and c=174.99Å, $\alpha=\beta=\gamma=90$.

2-3. (cancelled)

4. (previously presented) A composition according to claim 16 wherein the protein diffracts X-rays for a determination of structure coordinates to a resolution of a value equal to or less than 3.0 Angstroms.

5. (cancelled)

6. (currently amended) A method for forming a crystal of a protein comprising:

forming a crystallization volume comprising a precipitant solution and a protein that consists of residues 1-314 of ~~SEQ. ID No. 1~~ SEQ ID NO:1; and

storing the crystallization volume under conditions suitable for formation of a protein crystal.

7-8. (cancelled)

9. (previously presented) A method according to claim 6 wherein the protein diffracts X-rays for a determination of structure coordinates to a resolution of a value equal to or less than 3.0 Angstroms.

10. (currently amended) ~~A~~ The method according to claim 6 wherein the protein crystal has a crystal lattice in a $P4_122$ space group and unit cell dimensions, +/- 5%, of a=88.80Å b=88.80Å and c=174.99Å, $\alpha=\beta=\gamma=90$.

11-15. (cancelled)

16. (currently amended) A composition comprising a protein in crystalline form wherein the protein consists of residues 1-314 of ~~SEQ. ID No. 1~~ SEQ ID NO:1.

17. (cancelled)

18. (previously presented) The method according to claim 6 comprising:
diffracting the protein crystal to produce a diffraction pattern; and
solving the structure of the protein crystal from the diffraction pattern.

19. (currently amended) A composition comprising an isolated protein consisting of residues 1-314 of ~~SEQ. ID No. 1~~ SEQ ID NO:1.

20. (currently amended) The method according to claim 18 wherein the protein crystal has a crystal lattice in a $P4_122$ space group and unit cell dimensions, +/- 5%, of a=88.80Å b=88.80Å and c=174.99Å, $\alpha=\beta=\gamma=90$.

21. (previously presented) The method according to claim 18, the method further comprising:
performing rational drug design using the solved structure; and
identifying an entity that associates with the protein.

22. (previously presented) The method according to claim 21 further comprising selecting one or more entities based on the rational drug design and contacting the selected entities with the protein.

23. (previously presented) The method according to claim 21 further comprising measuring an activity of the protein when contacted with the one or more entities.